Cost-effectiveness of ambulatory blood pressure: A reanalysis

Hypertension

Volumn 47, Issue 1, 2006, Pages 29-34

  Krakoff, Lawrence R ^a  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Ambulatory blood pressure monitoring, ambulatory; Cost benefit analysis; Hypertension, white coat

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; SCREENING; WHITE COAT HYPERTENSION;

BLOOD PRESSURE MONITORING, AMBULATORY; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; UNITED STATES;

EID: 31744445248     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000197195.84725.66     Document Type: Article

References (40)

1. Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA. 1983;249:2792-2798.
2. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
3. Clement D, De Buyzere M, De Bacqer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van der Niepen P, O'Brien E, for the Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-2415.
4. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure and mortality. Hypertension. 2005;45:499-504.
5. Fagard RH, Staessen JA, Thijs L, Bulpitt CJ, Clement D, de Leeuw PW, Jaaskivi M, Mancia G, O'Brien E, Palatini P, Tuomilehto J, Webster J. Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension. J Hypertens. 2004;22:81-87.
6. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den HE, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;461:156-161.
7. Pickering TG. White coat hypertension. Curr Op Nephrol Hypert. 2002;5:192-198.
8. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T, Kario K. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-208.
9. Bjorklund K, Lind L, Vessby B, Andren B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation. 2002;106:63-68.
10. Chobanian AV, Bakris GL, Black HR, Green L, Izzo JLJr, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-2572.
11. Guidlines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension*. J Hypertens. 2003;21:1011-1053.
12. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the Am Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142-161.
13. Ernst ME, Bergus GR. Favorable patient acceptance of ambulatory blood pressure monitoring in a primary care setting in the United States: a cross-sectional survey. BMC Fam Pract. 2003;4:15.
14. Krakoff LR, Eison H, Phillips RH, Leiman S, Lev S. Effect of ambulatory blood pressure monitoring on the diagnosis and cost of treatment for mild hypertension. Am Heart J. 1988;116:1152-1154.
15. Krakoff LR, Schechter C, Fahs M, Andre M. Ambulatory blood pressure monitoring: is it cost-effective? J Hypertens. 1991;9:S28-S30.
16. Polonia JJ, Gama GM, Silva JA, Amaral C, Martins LR, Bertoquini SE. Sequential follow-up clinic and ambulatory blood pressure evaluation in a low risk population of white-coat hypertensives and normotensives. Blood Pressure Monitoring. 2005;10:57-64.
17. Odell TW, Gregory MC. Cost of hypertension treatment. J Gen Intern Med. 1995;10:686-688.
18. Ramsey SD, Neil N, Sullivan SD, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract. 1999;12:105-114.
19. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: Can better care cost less? JAMA. 2004;291:1850-1856.
20. Vasan RS, Larson MG, Leip E, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study. Lancet. 2001;358:1682-1686.
21. Vasan RS, Beiser A, Seshadri S, Larson MG, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003-1010.
22. Vasan RS, Levy D. Rates of progression to hypertension among non-hypertensive subjects: implications for blood pressure screening. Euro Heart J. 2004;23:1067-1070.
23. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951.
24. Bidlingmeyer I, Burnier M, Bidlingmeyer M, Waeber B, Brunner HR. Isolated office hypertension: a prehypertensive state? J Hypertens. 1996;3:327-332.
25. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
26. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, Johnston C, McNeil JJ, Macdonald G, Marley JE, Morgan TO, West MJ, for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
27. Ewald B, Pekarsky B. Cost analysis of ambulatory blood pressure monitoring in initiating antihypertensive drug treatment in Australian general practice. Med J Aust. 2002;176:580-583.
28. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, rzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J Hypertens. 2003;:1283-1289.
29. Grin JM, McCabe EJ, White WB. Management of hypertension after ambulatory blood pressure monitoring. Ann Int Med. 1993;118:833-837.
30. Richards C, Sutherland M, Gough K, Padfield PL. Direct access ambulatory BP monitoring- the Edinburgh experience. Blood Pressure Monitoring. 2005;9:287-291.
31. Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D. Comparison of acceptability of and preferences for different methods of measuring blood pressure in primary care. BMJ. 2002;325:258-259.
32. Redon J, Campos C, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 2001;31:712-718.
33. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien DE, Fagard R, for the Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. JAMA. 1997;278:1065-1072.
34. Lorgelly P, Siatis I, Brooks A, Slinn B, Millar-Craig MW, Donnelly R, Manning G. Is ambulatory blood pressure monitoring cost-effective in the routine surveillance of treated hypertensive patients in primary care? Br J Gen Pract. 2003;53:794-796.
35. Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med. 1999;131:564-572.
36. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508-515.
37. Bombelli M, Sega R, Facchetti R, Corrao G, Friz HP, Vertemati AM, Sanvito R, Banfi E, Carugo S, Primitz L, Mancia G. Prevalence and clinical significance of a greater ambulatory versus office blood pressure ('reversed white coat' condition) in a general population. J Hypertens. 2005;23:513-520.
38. Palatini P. Masked hypertension: how can the condition be detected? Blood Press Monit. 2004;9:297-299.
39. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 2002;40:795-796.
40. Mcgrath BP. Ambulatory blood pressure monitoring. Med J Aust. 2002;176:588-592.